✓After hours - Last update: Oct 5, 2026, 4:39 PM ET
Source: daily_prices:fmp_change_percent
Related research: Vaxcyte (PCVX) Surges ~35% as VAX-31 Meets All Primary Endpoints in Pivotal Phase 3 Trial →
Market closed · After hours · 5:43 PM ET
Last update: Oct 5, 2026, 5:17 PM ETMarket closed·64 changes confirmed today
Track the stock moves that actually matter.
BestStocks detects meaningful changes across price, volume, earnings, filings, valuation, analyst revisions, and risk signals — and shows you the evidence behind each one.
1,000 equities monitored14 signal typesCross-checked against SEC EDGARMedian detection lag ~41s
Investment research built around change detection.
Showing:
BestStocks identifies what changed across companies and sectors, explains why it matters, and helps investors spot opportunities worth investigating.
Changes History →
✓After hours - Last update: Oct 5, 2026, 4:45 PM ET
⚡Material / Earnings✓High confidence
What changed: Twist Bioscience Corporation (TWST) moved +7.91% from $189.97 to $205.00 on 2026-10-05, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor TWST's earnings announcement on 2026-11-13 for actual results versus the −$0.44 consensus estimate.
✓After hours - Last update: Oct 5, 2026, 4:44 PM ET
🛡Material / Earnings✓High confidence
What changed: Praxis Precision Medicines, Inc. (PRAX) moved -5.20% from $299.12 to $283.56 on 2026-10-05. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was near its 5-day average, indicating the move was not driven by unusual trading activity.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor the 2026-11-04 earnings announcement for updates on clinical progress or cash runway.
✓After hours - Last update: Oct 5, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Repligen Corporation (RGEN) moved +6.01% from $178.75 to $189.50 on 2026-10-05. We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Repligen's Q3 earnings on 2026-10-27 will be the next concrete catalyst to assess whether results align with or diverge from the $0.46 consensus estimate.
✓After hours - Last update: Oct 5, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Dillard's, Inc. (DDS) moved +5.16% from $661.23 to $695.35 on October 5, 2026. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred on light volume (33% of the 5-day average) and coincided with DDS reaching a new 30-day high.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor DDS earnings announcement on November 12, 2026, and watch for volume confirmation if the stock sustains levels above $695.
✓After hours - Last update: Oct 5, 2026, 4:39 PM ET
🛡Material / Earnings✓High confidence
What changed: Sunoco LP (SUN) moved -5.55% from $74.00 to $69.89 on 2026-10-05. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears to be technical, with SUN reaching a new 30-day low on volume near its 5-day average.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Sunoco LP earnings report expected 2026-11-03.
✓After hours - Last update: Oct 5, 2026, 4:39 PM ET
⚡Material / Earnings✓High confidence
What changed: Paramount Skydance Corporation Class B Common Stock (PSKY) moved +5.56% on October 5, 2026, as the company prepares for the imminent close of its $111 billion acquisition of Warner Bros. Discovery, expected as early as October 6, 2026. The same day, Paramount is finalizing the transition of its Class B listing from Nasdaq to the New York Stock Exchange.
Source: daily_prices:fmp_change_percent
Changes History →What's next
What to watch
Monitor for official announcement of the Warner Bros. Discovery acquisition close and the start of PSKY trading on the NYSE to confirm the transition and any trading adjustments.
✓After hours - Last update: Oct 5, 2026, 12:22 PM ET
📊Valuation✓High confidence
What changed: Craig-Hallum downgraded Sphere Entertainment from Buy to Hold and cut its price target from $170 to $132, triggering a 12.94% intraday drop to $111.66. The stock gapped down at open and accelerated lower on elevated volume (6.12x historical average at 170 minutes into the session), sliding from $128.25 as the analyst flagged ongoing profitability concerns despite recent revenue beats.
Detected Oct 5, 3:50 PM ET
Changes History →What's next
What to watch
Sphere Entertainment earnings scheduled for November 3, 2026 (consensus EPS estimate: −$1.53); monitor whether other analysts revise price targets or ratings in response to Craig-Hallum's move.
✓After hours - Last update: Oct 5, 2026, 10:32 AM ET
Intraday updates2 updates
3:50 PM ETLATESTValuation✓ High confidence
Schneider Electric agreed to acquire PTC in an all-cash deal at $205 per share, announced October 5, 2026 (defenseworld.net, invezz.com). PTC shares surged +34.31% from $144.03 to $193.44, reflecting the 42.3% premium to the previous close embedded in the offer price. Volume jumped to 14.5M shares (29.4x the time-adjusted expected level), driven by merger-related trading activity.
11:10 AM ETActivity✓ High confidence
PTC Inc. moved +34.60% intraday from $144.03 to $193.86. invezz.com: Why Schneider Electric stock tumbled 9% after its $22.6B PTC acquisition
▤
Changes History →Related research: PTC Inc. (PTC) Jumps ~35% as Schneider Electric Agrees to a $22.6 Billion Cash Takeover →
What's next
What to watch
Shareholder vote (date TBD) and regulatory approvals through Q3 2027; PTC earnings on November 4, 2026 (consensus $1.97 EPS) may provide updates on deal progress and conditions.
✓After hours - Last update: Oct 5, 2026, 3:32 PM ET
📊Valuation✓High confidence
What changed: Liquidia shares fell 4.81% to $27.26 following a September 30 Delaware federal court ruling that its lead drug Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for pulmonary hypertension with interstitial lung disease (PH-ILD), per Raymond James and BofA analyst downgrades cited on Yahoo Finance. Major Wall Street firms cut price targets amid concern over potential sales injunctions or forced label changes limiting Yutrepia's market. Volume was elevated at 1.60x historical average at the 360-minute mark.
Detected Oct 5, 3:50 PM ET
Changes History →What's next
What to watch
Liquidia's planned appeal decision and FDA label modification request; earnings scheduled for November 2, 2026 (consensus EPS $0.90).
✓After hours - Last update: Oct 5, 2026, 1:22 PM ET
📊Valuation✓High confidence
What changed: Illumina rose 4.94% to $286.52, driven by positive momentum from strong Q2 earnings (revenue $1.09B, +4.8% YoY) and raised full-year EPS guidance announced Jul 8, 2026, per Yahoo Finance. Analyst upgrades from firms including UBS and Piper Sandler, plus continued institutional buying following S&P 500 inclusion, are sustaining bullish sentiment. Volume of 1.5M shares is running 0.61x average for this point in the session.
Detected Oct 5, 3:50 PM ET
Changes History →What's next
What to watch
ILMN earnings on 2026-10-29 (consensus EPS estimate $1.36); track whether the company sustains the guidance beat trajectory or signals any deceleration in NovaSeq X adoption.
✓After hours - Last update: Oct 5, 2026, 12:31 PM ET
📊Valuation✓High confidence
What changed: Guardant Health rose 3.30% to $183.67 after the company announced publication of positive COSMOS-MEL01 study results in *Cancer Research Communications*, demonstrating the tissue-free Guardant Reveal blood test's ability to detect molecular residual disease in stage II–III melanoma patients (web_catalyst via MarketWatch and Yahoo Finance). This marks the first prospective, multicenter evaluation of this application. Volume was below average at 0.58x expected for this point in the session.
Detected Oct 5, 3:50 PM ET
Changes History →What's next
What to watch
Guardant Health earnings scheduled for 2026-10-28 (consensus EPS estimate: −$0.75); monitor for guidance updates on COSMOS-MEL01 commercialization timelines and insurance reimbursement progress.
Latest research
View all research →In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisOctober 5, 2026 · 9 min read
Vaxcyte (PCVX) Surges ~35% as VAX-31 Meets All Primary Endpoints in Pivotal Phase 3 Trial
Vaxcyte surged to roughly $76 on October 5 — up about 35% after opening near $87 (about +54%) — when it reported positive topline data from OPUS-1, the pivotal adult Phase 3 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine. The trial met all of its prespecified primary endpoints on immune-response and safety measures: in adults 50 and older, VAX-31 met non-inferiority on all 20 serotypes it shares with Pfizer's Prevnar 20 and 17 of the 19 it shares with Merck's Capvaxive (the two exceptions cleared only a less-stringent historical bar), and superiority on the three serotypes unique to VAX-31, with safety similar to the incumbents. It is the profile a broader, 31-valent shot needs to take share in a multi-billion-dollar adult pneumococcal market — and the market priced it as a transfer of value, with Pfizer down about 1.6% and Merck about 3.4% while the biotech index was flat. Vaxcyte is still a clinical-stage, pre-revenue company — a roughly $1 billion annual loss, no P/E, and years from revenue, with two more Phase 3 trials due in 2027 and a planned filing in 2028 — but about $2.5 billion of cash and investments gives it runway, and sell-side targets sit well above the current price (Guggenheim raised its target to $125 the same day; Mizuho and Jefferies reiterated standing Buys at $163 and $146). The stock's gap-up-then-fade captures the tension between clearly good data and the execution still ahead.
PCVXRead →
Stock AnalysisOctober 5, 2026 · 10 min read
PTC Inc. (PTC) Jumps ~35% as Schneider Electric Agrees to a $22.6 Billion Cash Takeover
PTC Inc. jumped about 35% to roughly $194.49 on October 5 after Schneider Electric agreed to acquire the industrial-software maker in an all-cash deal at $205 a share — valuing PTC's equity near $22.6 billion, a 42.3% premium to Friday's close, in what would be Schneider's largest acquisition ever. With a firm cash bid in hand, the stock stopped trading on fundamentals and started trading on deal arithmetic: it gapped toward the offer but settled about 5% below it, a merger spread that prices the time and risk to a close expected by the third quarter of 2027, subject to a PTC shareholder vote and antitrust and CFIUS clearances. The logic is industrial software and AI — PTC's design and lifecycle tools (Creo, Windchill) carry an 84% gross margin and about $935 million of free cash flow, and the company had de-rated with the software group on AI fears, which is what made it available at a price Schneider would pay a premium over. The deal is also a read-through for the sector: design-software peers like Autodesk and Dassault Systèmes rose in sympathy as the price reframed what these assets are worth, while Loop Capital, Baird and Rosenblatt all moved PTC toward Hold/Neutral at the deal price — the textbook reaction to a fixed cash bid. The investment question now is simply whether the deal closes.
PTCRead →
Stock AnalysisOctober 2, 2026 · 9 min read
Western Digital (WDC) Drops ~10% as Toshiba Plans to Double AI/Data-Center HDD Capacity
Western Digital fell about 10% to roughly $415.50 intraday on October 2 after a report, traced to Nikkei, that Toshiba plans to double its production capacity for the high-capacity hard drives used in AI data centers — a roughly ¥60 billion (about $380 million) investment centered on the Philippines, for its fiscal year ending March 2028. The move had nothing to do with Western Digital itself: the stock's run, up about 216% over the past year, was built on a concentrated, supply-disciplined HDD industry keeping drive prices and margins firm, and a credible new source of capacity from the smallest of the three makers directly challenges that. It was a hard-drive-specific supply scare amid a broadly firm tech tape, not a tech selloff — Seagate, the other pure HDD maker, fell about 12%, while Micron slipped under 1% and Nvidia rose. As a pure-play HDD company after spinning off its flash business as SanDisk, Western Digital has no segment to cushion a pricing threat, and at roughly 21 times forward earnings and 12 times sales its premium multiple embeds an assumption that constrained supply keeps pricing elevated. The analyst picture is bullish — a Buy consensus averaging near $665 — but it predates the Toshiba report, and the open question is how far those targets come down as the Street weighs what added supply means for pricing.
WDCRead →
Stock AnalysisSeptember 30, 2026 · 9 min read
Fair Isaac (FICO) Crashes ~26% as FHFA Moves to Equalize VantageScore Mortgage Pricing
Fair Isaac fell about 26.5% to $617.87 on September 29 — its steepest single-day decline in decades — after FHFA Director Bill Pulte said, in a post late the prior evening, that Fannie Mae and Freddie Mac will move to a single mortgage pricing grid that treats loans scored with Classic FICO and rival VantageScore 4.0 equally, removing the 20-point adjustment that had kept FICO the default. The move strikes FICO's most profitable franchise: its Scores segment runs ~90% operating margins, and the company had just doubled its wholesale mortgage royalty to about $10.00 per score for 2026, while VantageScore 4.0's mortgage score is $0.99 (TransUnion committed through 2028) — so lenders now face a rival score that is roughly ten times cheaper and, once the change takes effect, priced identically by the GSEs. The repricing landed predominantly on FICO: the two publicly traded bureaus that jointly own VantageScore, Equifax and TransUnion, fell materially less — about 3% — and the S&P 500 was flat. Volume ran about seven times normal, and the stock is now down roughly 69% from its 52-week high. Analyst targets are splitting between a stale ~$1,435 consensus and fresh, event-aware resets — Huber Research downgraded to Underweight at $710, while Goldman cut to $1,322 but kept a Buy — capturing how uncertain the migration path is. After the drop FICO trades near 12 times forward earnings, but the multiple now hinges on how fast lenders actually switch.
FICORead →
Stock AnalysisSeptember 18, 2026 · 8 min read
Nucor (NUE) Drops ~6% as Q3 Guidance of $5.55–$5.65 Lands Below Street Estimates
Nucor fell about 6% to roughly $249 on September 18 after guiding, on Thursday evening, to third-quarter earnings of $5.55–$5.65 a share — a strong number that nonetheless landed about 9% below the roughly $6.17 consensus. The miss is one of degree, not direction: the guide would still be a sequential increase from Q2's ~$5.04 and a huge jump from the $2.63 Nucor earned a year ago, with the core steel mills and steel products segments guided up, but a weaker raw-materials segment and the absence of two second-quarter tailwinds — a ~$130 million cash refund and a ~$61 million Helion valuation gain — drove the shortfall. On a cyclical up about 74% over the past year to near record highs, a guide below expectations was enough to trigger a pullback — and it was a sector signal, not just a Nucor one: Steel Dynamics guided its own Q3 below consensus the same evening, so the whole steel group sold off together, with Steel Dynamics off about 4.5% and the steel ETF lower while the S&P 500 barely moved. Analysts mostly trimmed targets but kept their Buys, leaving a consensus near $285, and the stock now trades near 13 times the 2026 earnings estimate. The real question the soft guide raises is whether the steel cycle is pausing or peaking, with 2027 earnings growth already seen slowing to low single digits.
NUERead →
Stock AnalysisSeptember 18, 2026 · 9 min read
Netflix (NFLX) Drops as Wells Fargo Turns Bear With a Street-Low $57 Target on Engagement Worries
Netflix fell about 4% to roughly $72 on September 18 after Wells Fargo's Steven Cahall downgraded the stock to Underweight from Equal Weight and cut his price target to a Street-low $57 from $80. (Prices are split-adjusted after Netflix's 10-for-1 split in November 2025.) The call is about engagement, not profitability: after reviewing more than 150 titles, Cahall estimates second-half engagement (hours viewed per subscriber per day) falls about 4% year-over-year — with Top-100 Originals viewing down about 21% — raising churn risk into 2027, and his $57 rests on a lower multiple (15 times 2027 earnings, down from 21). It is a rare bear — the lone Sell in the tracked coverage — against a bullish Street, whose average target near $95 sits about 30% above the price, and it landed on a stock already down about 40% over the year. The move was Netflix-specific — Disney and other media names fell far less — and the underlying business remains highly profitable, growing revenue ~16% at a ~30% operating margin with ~$11 billion of free cash flow. The debate is about how fast Netflix can still grow, and the annual viewership report Netflix will publish in early 2027 is the catalyst both sides are waiting on.
NFLXRead →